GTHX | G1 Therapeutics, Inc.
Quick infos Headquarters: North Carolina, United States Trade prices Volume: Market Cap: 220.79M Prev closed: Open: 8.96 High: 9.22 Low: 8.73 52 week low: 8.04 52 week high: 26.69 Dividends: No Dividends Next ER: November 2, 2022 Before Market Opens
Company Profile Our mission is to discover, develop and deliver innovative therapies that improve the lives of those affected by cancer.
Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing two novel therapies for people living with cancer.
Earnings History Date EPS / Forecast Revenue / Forecast February 22, 2023 November 9, 2022 - / -0.6409- / 23.33MAugust 3, 2022 -0.92 / -1.0210.57M / 9.14MBeat! May 4, 2022 -1.15 / -0.97986.9M / 6.37MBeat! February 23, 2022 -0.94 / -1.035.8M / 5.71MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 3, 2022 8.70 8.86 9.17
7.83
2.43M 4.69% Aug 2, 2022 8.31 8.03 8.45
8.03
540.73K 2.21% Aug 1, 2022 8.13 8.25 8.71
7.98
1.14M -2.4% Jul 29, 2022 8.33 8.25 8.36
8.00
466.13K 0.24% Jul 28, 2022 8.31 8.17 8.31
7.82
498.24K 0.85% Jul 27, 2022 8.24 8.35 8.47
7.95
652.95K 0.61% Jul 26, 2022 8.19 8.10 8.77
7.88
1.21M -0.12% Jul 25, 2022 8.20 8.19 8.36
8.06
466.09K 0.12% Jul 22, 2022 8.19 8.51 8.62
7.96
573.45K -3.76% Jul 21, 2022 8.51 8.12 8.52
8.07
629.49K 4.55% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2008 Employees:104 News
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket fool.com Nov 18, 2022 4:45 pm
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates finance.yahoo.com Nov 18, 2022 7:45 am
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights finance.yahoo.com Nov 18, 2022 6:30 am
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC) finance.yahoo.com Nov 18, 2022 6:28 am G1 Therapeutics announces stock offering seekingalpha.com Nov 18, 2022 5:34 am
G1 Therapeutics Announces Pricing of Offering of Common Stock finance.yahoo.com Nov 17, 2022 8:12 pm
Newsflash: G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Revenue Forecasts finance.yahoo.com Nov 3, 2022 8:17 am G1 Therapeutics rises as trilaciclib potentially reduces adverse events linked with Trodelvy seekingalpha.com Nov 2, 2022 7:14 pm G1 Therapeutics GAAP EPS of -$0.59 beats by $0.04, revenue of $23.6M beats by $0.33M seekingalpha.com Nov 2, 2022 6:36 pm
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year? finance.yahoo.com Oct 28, 2022 9:40 am
G1 Therapeutics (NASDAQ:GTHX investor three-year losses grow to 52% as the stock sheds US$50m this past week finance.yahoo.com Oct 21, 2022 6:42 am
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year? finance.yahoo.com Oct 12, 2022 9:40 am
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com Sep 7, 2022 8:00 am
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect? finance.yahoo.com Aug 8, 2022 9:55 am
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com Aug 3, 2022 7:45 am
Industry Analysts Just Upgraded Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Revenue Forecasts By 10% finance.yahoo.com Jul 31, 2022 8:03 am
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer finance.yahoo.com Jun 13, 2022 7:00 am
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Jun 1, 2022 4:45 pm
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Oct 3, 2022 5:00 pm
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Sep 1, 2022 5:22 pm This company doesn't provide a dividend.
Key Persons Chief Medical Officer : Raj Malik Talk about G1 Therapeutics, Inc. below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
investor.g1therapeutics.com If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
